Prostate cancer chemotherapy by intratumoral administration of Docetaxel-Mesoporous silica nanomedicines

• Published in: International journal of pharmaceutics 2024-10, Vol.664, p.124623, Article 124623
• Main Authors: Rivero-Buceta, Eva, Bernal-Gómez, Adrián, Vidaurre-Agut, Carla, Lopez Moncholi, Eric, María Benlloch, Jose, Moreno Manzano, Victoria, David Vera Donoso, César, Botella, Pablo
• Format: Article
• Language: English
• Subjects: Docetaxel; Intratumoral administration; Mesoporous silica nanoparticles; Prostate cancer
• ISSN: 0378-5173; 1873-3476; 1873-3476
• DOI: 10.1016/j.ijpharm.2024.124623

[Display omitted] •Nanomedicines of mesoporous silica nanoparticles and docetaxel.•Focal therapy of human prostate adenocarcinoma by intratumoral administration over a xenograft mouse model.•High antitumor activity and good tolerability at low dosing level. Docetaxel (DTX) is a recommended treatment in patients with metastasic prostate cancer (PCa), despite its therapeutic efficacy is limited by strong systemic toxicity. However, in localized PCa, intratumoral (IT) administration of DTX could be an alternative to consider that may help to overcome the disadvantages of conventional intravenous (IV) therapy. In this context, we here present the first in vivo preclinical study of PCa therapy with nanomedicines of mesoporous silica nanoparticles (MSN) and DTX by IT injection over a xenograft mouse model bearing human prostate adenocarcinoma tumors. The efficacy and tolerability, the biodistribution and the histopathology after therapy have been investigated for the DTX nanomedicine and the free drug, and compared with the IV administration of DTX. The obtained results demonstrate that IT injection of DTX and DTX nanomedicines allows precise and selective therapy of non-metastatic PCa and minimize systemic diffusion of the drug, showing superior activity than IV route. This allows reducing the therapeutic dose by one order and widens substantially the therapeutic window for this drug. Furthermore, the use of DTX nanomedicines as IT injection promotes strong antitumor efficacy and drug accumulation at the tumor site, improving the results obtained with the free drug by the same route.